Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T Bowen

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Seminars in Hematology|April 18, 2006
Etiology of acute myeloid leukemia in the elderlyDavid T Bowen
Hematological Oncology|September 9, 2005
Chronic myelomonocytic leukemia: lost in classification?David T Bowen
Best Practice & Research. Clinical Haematology|February 11, 2014
Occupational and environmental etiology of MDSDavid T Bowen
Seminars in Oncology|August 9, 2005
Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patientsDavid T Bowen
Leukemia Research Reports|February 25, 2015
An intensive approach to treatment for older patients with relapsed isolated NPM1 mutated AMLSrivasavi Dukka, David T Bowen
Expert Reviews in Molecular Medicine|February 16, 2010
Epigenetic mechanisms regulating normal and malignant haematopoiesis: new therapeutic targets for clinical medicineConstanze Bonifer, David T Bowen
International Journal of Hematology|May 31, 2003
Oxidative stress and the myelodysplastic syndromesMorag J Farquhar, David T Bowen
Leukemia Research Reports|December 28, 2013
Durable second complete remissions with oral melphalan in hypocellular Acute Myeloid Leukemia and Refractory Anemia with Excess Blast with normal karyotype relapsing after intensive chemotherapyAnnika M Whittle, Sylvia Feyler, David T Bowen
Leukemia Research|July 11, 2006
Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitorsBjoern Biedermann, Diana Gil, David T Bowen, et al.
Haematologica|November 9, 2004
Latency of onset of de novo myelodysplastic syndromesPei-shan Wu, Annette E Hay, Giles E Thomas, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Seminars in Hematology|April 18, 2006
Etiology of acute myeloid leukemia in the elderlyDavid T Bowen
Hematological Oncology|September 9, 2005
Chronic myelomonocytic leukemia: lost in classification?David T Bowen
Best Practice & Research. Clinical Haematology|February 11, 2014
Occupational and environmental etiology of MDSDavid T Bowen
Seminars in Oncology|August 9, 2005
Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patientsDavid T Bowen
Leukemia Research Reports|February 25, 2015
An intensive approach to treatment for older patients with relapsed isolated NPM1 mutated AMLSrivasavi Dukka, David T Bowen
Expert Reviews in Molecular Medicine|February 16, 2010
Epigenetic mechanisms regulating normal and malignant haematopoiesis: new therapeutic targets for clinical medicineConstanze Bonifer, David T Bowen
International Journal of Hematology|May 31, 2003
Oxidative stress and the myelodysplastic syndromesMorag J Farquhar, David T Bowen
Leukemia Research Reports|December 28, 2013
Durable second complete remissions with oral melphalan in hypocellular Acute Myeloid Leukemia and Refractory Anemia with Excess Blast with normal karyotype relapsing after intensive chemotherapyAnnika M Whittle, Sylvia Feyler, David T Bowen
Leukemia Research|July 11, 2006
Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitorsBjoern Biedermann, Diana Gil, David T Bowen, et al.
Haematologica|November 9, 2004
Latency of onset of de novo myelodysplastic syndromesPei-shan Wu, Annette E Hay, Giles E Thomas, et al.
Pageof 3